
## A resolution addressing entheogenic plant practices



Decriminalize Nature Missoula



**DECRIMINALIZENATURE.ORG** 

## Entheogens Defined

- Entheogens are defined herein as the full spectrum of plants, fungi, and natural materials and/or their extracted compounds, limited to those containing the following types of compounds: indole amines, tryptamines, and phenethylamines
- Entheogens can benefit psychological and physical wellness, support and enhance religious and spiritual practices, and can reestablish human's unalienable and direct relationship to nature.



art by Elmer W. Smith

## Current Research: Physical Health

### **Cell Reports**

### **Psychedelics Promote Structural and Functional Neural Plasticity**

#### **Graphical Abstract**



#### Authors

Calvin Ly, Alexandra C. Greb, Lindsay P. Cameron, ..., Kassandra M. Ori-McKenney, John A. Gray, David E. Olson

Journal of Psychoactive Drugs, 47 (5), 372-381, 2015 Copyright © Taylor & Francis Group, LLC ISSN: 0279-1072 print/2159-9777 online DOI: 10.1080/02791072.2015.1107664

Routledge Taylor & Francis Group

Article

### **Indoleamine Hallucinogens in Cluster** Headache: Results of the **Clusterbusters Medication Use Survey**



### Current Research: Recidivism, Crime Reduction, IPV





### Current Research: Curing Substance Use Issues

THE AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE http://dx.doi.org/10.1080/00952990.2017.1320802 Taylor & Francis Taylor & Francis Group

OPEN ACCESS

### Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes

Thomas Kingsley Brown, PhD<sup>a</sup> and Kenneth Alper, MD<sup>b</sup>

<sup>a</sup>University of California, San Diego, CA, USA; <sup>b</sup>Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, USA

### Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes

#### Deborah C. Mash<sup>1,2\*</sup>, Linda Duque<sup>1</sup>, Bryan Page<sup>3</sup> and Kathleen Allen-Ferdinand<sup>4</sup>

<sup>1</sup> Department of Neurology, Leonard M. Miller School of Medicine, Miami, FL, United States, <sup>2</sup> Department of Molecular and Cellular Pharmacology, Leonard M. Miller School of Medicine, Miami, FL, United States, <sup>3</sup> Department of Anthropology, University of Miami, Coral Gables, FL, United States, <sup>4</sup> General Medical Practice, Basseterre, Saint Kitts and Nevis



Current Drug Abuse Reviews, 2014, 7, 101-116

Psychedelics as Medicines for Substance Abuse Rehabilitation: Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca

101

Michael Winkelman

#### **ORIGINAL RESEARCH article**

Front. Psychiatry, 24 April 2018 | https://doi.org/10.3389/fpsyt.2018.00136

### Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca

## Current Research: Depression & Anxiety

Original Paper

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

Natalie Gukasyan<sup>1</sup>, Alan K Davis<sup>1,2</sup>, Frederick S Barrett<sup>1</sup>, Mary P Cosimano<sup>1</sup>, Nathan D Sepeda<sup>1</sup>, Matthew W Johnson<sup>1</sup> and Roland R Griffiths<sup>1,3</sup>



Journal of Psychopharmacology 2022, Vol. 36(2) 151–158 © The Author(s) 2022

Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/02698811211073759 journals.sagepub.com/home/jop

#### Psychological Medicine

cambridge.org/psm

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial

#### **Original Article**

Cite this article: Palhano-Fontes F et al (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychological Medicine 49, 655–663. https://doi.org/10.1017/50032391718001356

Received: 13 February 2018 Revised: 16 April 2018 Accepted: 24 April 2018 Fernanda Palhano-Fontes<sup>1,2</sup>, Dayanna Barreto<sup>2,3</sup>, Heloisa Onias<sup>1,2</sup>, Katia C. Andrade<sup>1,2</sup>, Morgana M. Novaes<sup>1,2</sup>, Jessica A. Pessoa<sup>1,2</sup>, Sergio A. Mota-Rolim<sup>1,2</sup>, Flávia L. Osório<sup>4,5</sup>, Rafael Sanches<sup>4,5</sup>, Rafael G. dos Santos<sup>4,5</sup>, Luís Fernando Tófoli<sup>6</sup>, Gabriela de Oliveira Silveira<sup>7</sup>, Mauricio Yonamine<sup>7</sup>, Jordi Riba<sup>8</sup>, Francisco R. Santos<sup>9</sup>, Antonio A. Silva-Junior<sup>9</sup>, João C. Alchieri<sup>10</sup>, Nicole L. Galvão-Coelho<sup>5,11</sup>, Bruno Lobão-Soares<sup>5,12</sup>, Jaime E. C. Hallak<sup>4,5</sup>, Emerson Arcoverde<sup>2,3,5</sup>, João P. Maia-de-Oliveira<sup>2,3,5</sup> and Dráulio B. Araújo<sup>1,2</sup>



Clinical Trial > J Psychopharmacol. 2016 Dec;30(12):1165-1180. doi: 10.1177/0269881116675512.

### Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Stephen Ross <sup>1</sup> <sup>2</sup> <sup>3</sup> <sup>4</sup> <sup>5</sup> <sup>6</sup>, Anthony Bossis <sup>7</sup> <sup>2</sup> <sup>4</sup>, Jeffrey Guss <sup>7</sup> <sup>2</sup> <sup>4</sup>, Gabrielle Agin-Liebes <sup>8</sup>, Tara Malone <sup>7</sup>, Barry Cohen <sup>9</sup>, Sarah E Mennenga <sup>7</sup>, Alexander Belser <sup>10</sup>, Krystallia Kalliontzi <sup>2</sup>, James Babb <sup>11</sup>, Zhe Su <sup>3</sup>, Patricia Corby <sup>2</sup>, Brian L Schmidt <sup>2</sup>

Original Paper

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

Roland R Griffiths<sup>1,2</sup>, Matthew W Johnson<sup>1</sup>, Michael A Carducci<sup>3</sup>, Annie Umbricht<sup>1</sup>, William A Richards<sup>1</sup>, Brian D Richards<sup>1</sup>, Mary P Cosimano<sup>1</sup> and Margaret A Klinedinst<sup>1</sup>



Journal of Psychopharmacology 2016, Vol. 30(12) 1181–1197 © The Author(s) 2016

Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269881116675513 jop.sagepub.com

## John Hopkins Study: "Healthy Normals"



Psychopharmacology DOI 10.1007/s00213-006-0457-5

ORIGINAL INVESTIGATION

### Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

R. R. Griffiths · W. A. Richards · U. McCann · R. Jesse

> J Psychopharmacol. 2008 Aug;22(6):621-32. doi: 10.1177/0269881108094300. Epub 2008 Jul 1.

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later


Rr Griffiths <sup>1</sup>, Wa Richards, Mw Johnson, Ud McCann, R Jesse

## Working Towards Humane Drug Policy

The United States government leads the world in rates of incarceration.

Arrests for entheogenic plants make it harder for Missoulians to:

Find secure employment
Find secure, affordable housing
Receive non-bias information



World Incarceration Rates


Source: International Centre for Prison Studies, World Prison Brief.<sup>3</sup>

## Working Towards Humane Drug Policy


The United States drug policies have disproportionately harmed Black, Indigenous, & People of Color (BIPOC) in the United States and in our community.

Arrests for entheogenic plants make it harder for Missoulians to:


- 1) Find secure employment
- 2) Find secure, affordable housing
- 3) Receive non-bias information



#### ARRESTS OVER TIME



Statewide marijuana possession arrest rates compared to all other drug arrest rates, per 100k people




(2010-2018 <u>Study</u> by ACLU)

## Working Towards Humane Drug Policy


### BY THE COUNTY

All counties with racial disparities above the national average (3.64x)



### Counties with the largest racial disparities

Counties with a pop. of >30,000, a data coverage of >50% and at least 25 marijuana possession arrests are included.



Arrests per 100k

Counties with missing data are striped. (2010-2018 Study by ACLU)

## Decriminalization Policy Nationwide

SHINGTON

Cities/states that have decriminalized entheogens: Denver, Oakland, Santa Cruz, Ann Arbor, Washtenaw County, MI, Oregon, Washington DC, Somerville, Cambridge, Northampton, Eastampton, Seattle, Arcata, Detroit, Port Townsend, Hazel Park



Quebec Ci

## After Decriminalization

### Denver study: No threat to public health or safety No known reports of emergencies or increased crime related to entheogens in the decriminalized cities

There has been no major increase in arrests related to the distribution of psilocybin mushrooms and no major cartel elements or organized crime. According to limited and preliminary university-level observational research for Colorado, most individuals set a positive intention prior to use and reported using psilocybin mushrooms for self exploration and mental health.

In March 2021, the Denver Psilocybin Mushroom Policy Review Panel (the Panel) unanimously agreed that decriminalizing psilocybin has not created any significant public health or safety issue since May 2019.



There have been no significant negative impacts on public safety as a result of decriminalizing psilocybin possession in the City of Denver.



## What This Means for City Council

- This not a complex legalization or regulation model, we are simply asking to not arrest individuals for growing, gathering, and gifting entheogens.
- To continue making entheogens not a funding priority for law enforcement or other agencies in Missoula
- To restrict budget expenditures for investigation, persecution, arrest for solely entheogenic issues
- To call upon the County Attorney to cease prosecution of persons involved in use of entheogens
- To instruct city's lobbyists to support at state level



# THANK YOU